Human immunodeficiency virus (HIV) continues to be a major contributor to morbidity and mortality worldwide, particularly in developing nations where high cost and logistical issues severely limit the use of current HIV therapeutics. This, combined HIV's high propensity to develop resistance, means that new antiviral agents against novel targets are still urgently required. We previously identified novel anti-HIV agents directed against the nuclear import of the HIV integrase ( 
| INTRODUCTION
Human immunodeficiency virus (HIV) remains one of the most widespread human pathogens despite the availability of highly active antiretroviral therapies. HIV has a high mutation rate, which is leading to the emergence of resistance among patients receiving these drugs resulting in a critical need to identify new targets and develop new classes of effective antiviral therapeutics (Wainberg, Mesplede, & Quashie, 2012) . A key step in HIV infection is transport into the infected cell nucleus of reverse transcribed viral cDNA packaged with both viral and cellular proteins into what is known as the preintegration complex (PIC; Bukrinsky et al., 1993; Piller, Caly, & Jans, 2003) . A key component of the PIC is the HIV integrase (IN) protein, which, along with other HIV-1 proteins, plays an important role in PIC nuclear entry (Hearps & Jans, 2006) ; once inside the nucleus, IN mediates integration of the viral cDNA into the host cell genome, followed by subsequent synthesis of the viral mRNA from this integrated DNA. Due to this critical role of IN, IN-targeted antiviral and dolutegravir. These compounds target IN-DNA binding, with resistance/cross-resistance between these various inhibitors already evident (Wainberg et al., 2012) ; clearly, new IN-targeting drugs with alternative mechanisms of action are urgently needed.
We previously performed a high-throughput screen to identify small molecule inhibitors of nuclear entry of IN, subsequently demonstrating their efficacy in limiting HIV infection (Wagstaff & Jans, 2006; Wagstaff, Rawlinson, Hearps, & Jans, 2011; Wagstaff, Sivakumaran, Heaton, Harrich, & Jans, 2012) . The inhibitors were specifically directed at the interaction between IN and its cellular nuclear import receptor complex, the importin (Imp) α/β1 heterodimer (Hearps & Jans, 2006) . In this study, we describe in detail a new set of novel IN nuclear transport inhibitors, which bind directly to IN as demonstrated by nuclear magnetic resonance (NMR) spectroscopy, determining that the region of inhibitor binding to IN is in the vicinity of the nuclear localisation signal (NLS) that confers interaction with Impα/β1, and showing that the extent of binding to the IN core domain correlates directly with the ability of the compound to inhibit IN nuclear transport in a permeabilised cell system. Importantly, compounds that inhibited the nuclear transport of IN were found to significantly decrease HIV viral replication, even in a dividing cell system. Significantly, two of the compounds were able to effect a significant reduction in the presence of specific nuclear forms of the HIV DNA (2-LTR circles), suggesting that the inhibitors work though blocking IN, and potentially PIC, nuclear import. The results represent a solid platform for further development of these specific inhibitors of HIV replication with therapeutic and prophylactic potential.
| RESULTS

| Specific inhibitors of HIV-1 IN nuclear transport bind directly to the IN core domain
We previously used high-throughput screening to identify a number of compounds, including mifepristone, that specifically inhibited IN binding to Impα/β1 and demonstrated that they can inhibit HIV-1 infection in a single cycle replication assay (Lundberg et al., 2013; Wagstaff et al., 2011; Wagstaff et al., 2012) . Several compounds identified, such as the FDA-approved ivermectin, were found to be broad spectrum inhibitors of Impα/β1-dependent nuclear import and to have antiviral activity towards a range of viruses as a consequence (Lundberg et al., 2013; Wagstaff et al., 2012) . To delineate the molecular interactions at play, we firstly tested the ability of mifepristone (Wagstaff et al., 2011) , as well as the chemically unrelated specific IN nuclear transport inhibitor molecule budesonide, described here for the first time, to bind directly to IN using heteronuclear single quantum coher- Mapping the residues that showed significant (>0.02 ppm) perturbation from the Apo (unbound) IN spectra, onto the crystal structure of the IN core domain (Figure 1b , blue residues) highlighted the ability of budesonide to perturb residues mapping to and around an α-helix located directly adjacent to the Impα/β1-recognised NLS of IN (Figure 1b , core residues highlighted in pink), which is located directly adjacent to the binding site on IN for the critical host-cell co-factor LEDGF/p75 (lens epithelial derived growth factor; Berthoux, Sebastian, Muesing, & Luban, 2007; Hou et al., 2008; Latham, la, Tinetti, Chalmers, & Tachedjian, 2016; Peat, Dolezal, Newman, Mobley, & Deadman, 2014) ; residue 186 of the NLS is also known to contribute to IN multimerisation (Berthoux et al., 2007) . Similarly, mifepristone impacted residues adjacent to the NLS on the opposite side of IN to budesonide, including those within a pocket known to be highly active for compound binding in fragment-based drug discovery trials (the IN fragment binding pocket; see Latham et al., 2016; Peat et al., 2014; Wielens et al., 2013) . These results clearly indicate direct binding of both budesonide and mifepristone to different sites on IN, both of which would appear to impact NLS-recognition by Impα/β1.
| IN core domain binding nuclear transport inhibitors reduce HIV IN nuclear accumulation
To confirm the ability of budesonide and mifepristone to inhibit IN nuclear import directly, we used an established in vitro nuclear import assay (Ghildyal et al., 2005; Hearps & Jans, 2006) . This system allows for quantitative analysis of the kinetics of the protein transport, rather than a single qualitative end point such as those provided by similar assays (Adam, Marr, & Gerace, 1990; Adam, Sternemarr, & Gerace, 1992) . Because semi-intact cells are used, it is possible to bypass the cell membrane to test inhibitors for intracellular mechanisms directly.
A routine inclusion in the assay is 70-kDa Texas red labelled dextran (TD70), exclusion of which indicates nuclear integrity (Bernis & Forbes, 2014; Hearps & Jans, 2006) . In this system, unperforated intact cells appear as large black cells (denoted by white * in Figure 2a ), whereas nuclei with intact nuclear envelopes appear as smaller TD70 excluding areas (marked by white arrows, Figure 2a) and overperforated nuclei with damaged/leaky nuclear envelopes fail to exclude TD70 properly (marked by white arrowheads, Figure 2a ; Bernis & Forbes, 2014; Lau et al., 2009) 
| IN nuclear import inhibitors inhibit HIV-1 infection
Infectious assays were performed to confirm that both budesonide and its most active analogue flunisolide are able to inhibit HIV-1 infec- and 2-LTR circles were expressed relative to late RT products to allow specific analysis of the nuclear import step. The full results for all compounds at all time points is included in the Supporting Information ( Figure S1 ).
As expected raltegravir had no consistent effect on the relative quantities of either the early or late HIV transcripts but produced a significant (up to six fold) increase in the ratio of 2-LTR circles to late HIV products, consistent with its role as an IN inhibitor, thereby driving transcripts towards the formation of alternative nuclear transcripts including 1-and 2-LTR circles. Conversely, efavirenz treatment significantly reduced the production of complete RT products, which was more pronounced later in infection (Figure 7b ), consistent with its action as a reverse transcription inhibitor. This inhibition carried forward into a complete lack of all nuclear HIV as expected.
In contrast to both of these, budesonide and flunisolide had no significant effect on the production of either the early or late HIV transcripts but significantly reduced the ratio of 2-LTR circles (Figure 7b) , consistent with the mechanism of action of these compounds being inhibition of PIC nuclear transport. Whether this is due to inhibition of PIC nuclear transport or inhibition of the IN protein only remains to be determined, but it is clear that the compounds characterised here in detail represent anti-HIV therapeutics with a unique mechanism of action.
Of several budesonide analogues examined, we identified flunisolide as a highly active analogue that can effect the same level of anti-HIV inhibition as budesonide, but with reduced toxicity, that has been associated with budesonide use in the clinic (Iborra, Alvarez-Sotomayor, & Nos, 2014; Saberi, Phengrasamy, & Nguyen, 2013 ), including potential cross-reactions with HIV protease inhibitor drugs such as ritonavir leading to acute hepatitis or Cushing's syndrome (Saberi et al., 2013) . Flunisolide, in contrast, does not appear to have these contraindications, being used extensively as a seasonal allergy spray with a high safety profile, including in HIV patients (Saberi et al., 2013) , demonstrating the potential to generate a compound that is both highly active against IN nuclear transport and that maintains a high safety profile, consistent with our findings here. Importantly, the limited structure activity relationship analysis performed here suggests that maintaining a small modification at the cyclic acetyl group attached to the steroidal D-ring appears to be important in maintaining activity and also in reducing toxicity. Relative levels of HIV virus was determined from the supernatant using a luciferase assay (as per Section 4), in TZM-bl cells. In parallel, cytotoxicity was measured (TZM-bl, c, and MT-2 cells, d) in triplicate for each dose using a cytotoxicity assay as well as visual assessment using light microscopy. Dose response curves were plotted from the percent inhibition of each dosage compared with untreated controls (% Relative Luciferase Units: %RLU), where the data represent the mean ± SEM, n = 3). EC 50 values were determined at noncytotoxic concentrations. Graphs represent a single typical experiment from a series of six (Tzm-bl) or four (MT-2) similar experiments and its active analogues, therefore lays the foundation for a future concerted rational drug design approach to generate a novel class of highly active nontoxic inhibitors of HIV targeting PIC nuclear transport and potentially incorporating activity against other functions of IN such as integration or LEDGF/p75 binding given the close proximity of the two binding sites. In this context, it is intriguing to note that Lysine 186 within the IN NLS has been found to play a critical role in IN multimerisation (Berthoux et al., 2007) , a key factor in INmediated activities such as integration (Faure et al., 2005) and nuclear import (Berthoux et al., 2007) (Sharma et al., 2014) appear to interact with residues on both sides of the multimerisation interface, including Threonine 174, which was also strongly perturbed by all of our IN inhibiting compounds. All four of the other residues identified as playing a role in multimerisation inhibition (Sharma et al., 2014) are located directly adjacent to the budesonide binding patch, implying that dual action nuclear import/multimerisation inhibitors may be able to be designed in the future. This possibility is a focus of ongoing work in this laboratory. 
| Bacterial expression plasmids
Bacterial expression vectors encoding (His) 6 -tagged IN (pINSD.His.Sol plasmid), GST-Impα (pET30a-Impα2), and GST-Impβ (pET30a Impβ1) have been described (Hearps & Jans, 2006; Wagstaff & Jans, 2006; .
| Cell culture
The hepatoma tissue culture (HTC) rat hepatoma cell line was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) foetal calf serum, L-glutamine, penicillin, and streptomycin. For in vitro transport assay experiments, HTC cells were trypsinised and seeded onto glass coverslips 2 days prior to use to achieve a confluency of 70% at the time of HIV transcripts) , which then undergoes a complex series of rearrangements to generate the preintegration complex (PIC; 2. Late HIV transcripts). The PIC undergoes nuclear import where it is integrated in the host genome to form the provirus, from which transcription will then occur. If integration fails to occur, the unintegrated viral DNA will form a number of nuclear forms of DNA including 1-and 2-LTR circles (3.2-LTR circles). The stages of infection targeted by the commercially available HIV drugs (efavirenz and raltegravir) or the IN nuclear import inhibitors are indicated in red. (b) Quadruplicate wells of MT-2 cells were infected with HIV in the presence of the indicated compounds and analysed by qPCR at the indicated times using specific primers for the presence of either early HIV (detected at 6 hr postinfection, Figure 7b (i)), late HIV (detected at 24-hr postinfection, Figure 7b (ii)) or 2-LTR transcripts (detected at 30-hr postinfection, Figure 7b (iii)). Results were relativised to a DMSO treated control and 2-LTR circles were further standardised to late RT products measures at the same time point. Results represent the mean ± scanning electron microscope (n = 4-budesonide/flunisolide or 3-Raltegravir/Efavirenz independent experiments), **P < 0.01, ****P < 0.0001, as compared to DMSO treated control (unpaired t-test). RAL; raltegravir, EFV; Efavirenz, Bud; budesonide, Flu; flunisolide experimentation. The MT-2 cell line (Harada, Koyanagi, & Yamamoto, 1985) , TZM-bl indicator cell line (Wei et al., 2002) , and 293 T cells were obtained through the NIH AIDS Research and Reference Reagent Program. MT-2 cells were cultured in RF-10 (RPMI 1640 supplemented with 10% foetal bovine serum, 100-U ml −1 penicillin, 100-μg ml −1 streptomycin, and 2-mM glutamine). TZM-bl and 293 T cells were cultured in DMEM-10 (DMEM supplemented with 10% FBS, 100-U ml −1 penicillin, 100-μg ml −1 streptomycin, and 2-mM glutamine). All cells were maintained in a humidified 37°C incubator with 5% CO 2 .
4.4 | Protein purification and Impα/β1 dimerisation His 6 -tagged IN protein was expressed in BL21 (DE3) bacteria as previously (Hearps & Jans, 2006) . Imp proteins were purified from bacteria as GST-fusion proteins under native conditions as described in Hubner et al. (1997) , Xiao et al. (1997) . Where appropriate, Impα and Impβ were predimerised at 13.6 μM for 15 min at room temperature to generate the Impα/β heterodimer for binding studies. 
| Biotinylation of Imp proteins
Impα was biotinylated for use in the AlphaScreen assay as previously (Wagstaff & Jans, 2006) , using the sulfo-NHS-biotin (sulfo-Nhydroxysuccinimide biotin) reagent (Pierce). Briefly, 3.5 mg of Imp was incubated with 250 μl of sulfo-NHS-biotin (1 mg dissolved in 150 μl of water) on ice for 2 hr. Unbound biotin was removed via a PD-10 column (GE Healthcare) and the resulting biotinylated protein was concentrated in an Amicon-30 concentration device.
| HSQC NMR
The IN construct used for NMR comprised the IN catalytic domain (residues 50-212) containing mutations Q53E,C56S,W131E,F185K, Q209E (Fitzkee, Masse, Shen, Davies, & Bax, 2010) . The coding sequence was cloned into plasmid vector pET28 into the NdeI and BamHI sites and expressed in BL21(DE3) RIL Escherichia coli using 15N-autoinduction media (Studier, 2005) and purified as described (Fitzkee et al., 2010) . Samples analysed using NMR contained 240-μM protein in 25-mM HEPES pH 6.8, 150-mM NaCl, 40-mM MgCl 2 , and 10% 2H 2 O in a sample volume of 150 μl in 3-mm NMR tubes. 1H,15N-HSQC spectra were acquired at 25°C on a Bruker AVANCE 600-MHz NMR spectrometer fitted with a CryoProbe, with spectral dimensions 160 (F1) × 2048 (F2) with 16 scans per increment and a recycle delay of 1.3 s. Compound addition was made from 100-mM d6-DMSO stocks.
| In vitro nuclear transport assay
Nuclear import of fluorescently labelled IN was investigated in vitro using mechanically perforated HTC cells as previously described (Jans, Jans, Briggs, Sutton, & Trapani, 1996) . Briefly, mechanical perforation was used to remove the plasma membrane of cells, but leave the nuclear membrane intact, and the perforated cells inverted on to a microscope slide over a chamber of artificial "cytoplasm" containing rabbit reticulocyte lysate, an ATP regenerating system (0.125-mg ml 
| AlphaScreen-based binding assay
The AlphaScreen assay was performed in triplicate in 384-well white opaque plates (PerkinElmer) essentially as previously (Wagstaff & Jans, 2006) . The assay was quantified on a PerkinElmer EnVision plate reader, triplicate values were averaged, and titration curves (sigmoidal)
were plotted using the Graphpad Prism graphing program. Values in the "hooking zone," where quenching of the signal occurs because of too much of either binding partner, were excluded from the final plot as previously (Wagstaff & Jans, 2006) . and noninfected TZM-bl cells (cytotoxicity) and incubated for 2 days at 37°C in 5% CO 2 . Equivalent concentrations of DMSO or media alone were used as controls. HIV inhibition was determined using the Steady-Glo luciferase assay system (Promega) as described previously (Tyssen et al., 2010) . Cytotoxicity was determined for each inhibitor using the CellTitre 96 AQueous One Solution cell proliferation reagent (Promega) as described previously (Pauwels et al., 1988 (from 10 7 to 1 copy per 10 μl) were used as standards for the early and late qPCR products. 2-LTR standards were generated by amplification of the 2-LTR region from infected MT-2 cells using the 2-LTR Fwd and Rev primers (above) and the product cloned into pTOPO.
Amplification was performed using Brilliant III SYBR qPCR mix (Agilent) according to the manufacturer's instructions and results normalised to infected DMSO-treated control samples within each experiment.
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Additional supporting information may be found online in the Supporting Information section at the end of the article. 
